%0 Journal Article
%T CA19-9与非小细胞肺癌预后的相关性<br>Association of CA19-9 with Prognosis of Non-Small Cell Lung Cancer
%A 热哈提·阿曼交尔
%A 刘春玲
%J Advances in Clinical Medicine
%P 585-590
%@ 2161-8720
%D 2024
%I Hans Publishing
%R 10.12677/ACM.2024.141081
%X 血清糖类抗原19-9 (简称CA19-9)是一种粘蛋白类糖蛋白肿瘤标志物，是细胞膜的一种糖脂，是迄今报道的对胰腺癌敏感性最高的标志物。后来发现CA19-9也存在于其他恶性肿瘤中，如非小细胞肺癌、乳腺癌和卵巢癌等。以往文献提示，CA19-9的表达水平在非小细胞肺癌不同的病理分型、临床分期、疗效及预后方面中可能存在差异。因此，就CA19-9在临床中对于癌症患者的诊治及预后方面的相关文献进行综述，重点阐释在非小细胞肺癌预后评估中的价值，为临床中针对CA19-9升高的非小细胞肺癌的个体化诊疗和全程管理提供参考。<br />
Serum carbohydrate antigen 19-9 (CA19-9 for short) is a mucin-type carbohydrate protein tumor marker, which is a glycolipid on cell membrane. It is the most sensitive marker for pancreatic can-cer reported so far. Later studies found that CA19-9 also exists in other malignancies, such as non-small cell lung cancer, breast cancer, ovarian cancer, etc. Previous literature suggests that the expression level of CA19-9 in non-small cell lung cancer may be different in terms of pathological classification, clinical staging, efficacy and prognosis. Therefore, a review of relevant literature on the diagnosis, treatment, and prognosis of cancer patients with CA19-9 in clinical practice is con-ducted, with a focus on elucidating its value in evaluating the prognosis of non-small cell lung cancer, providing reference for individualized diagnosis, treatment, and overall management of non-small cell lung cancer with elevated CA19-9 in clinical practice.
%K 非小细胞肺癌，糖类抗原19-9，诊疗，预后<br>Non-Small Cell Lung Cancer
%K Carbohydrate Antigen 19-9
%K Diagnosis and Treatment
%K Prognosis
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=79183